Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
Poet5
Poet5 Aug. 5 at 7:41 PM
$EYPT The first two trials were outstanding in every metric, safety, efficacy, 40-50% reduced treatment burden compared to Eylea, neuroanatomical structural integrity. I cannot imagine how the naive population in phase III would not bode equal or superior to former heavily treated population. The fears expressed about dilution is absurd! The extremely strong expectations and increased range estimates 40-65.00 are based on non-superiority. The shorting to hedge thinking is of not absurd, a bit of a head fake!
0 · Reply
explover
explover Aug. 5 at 7:16 PM
$EYPT why would they report the quarterly without warning in such a haste and without a 10-Q? It makes some sense as positioning for an offering after a successful LUGANO readout.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 5 at 6:23 PM
$EYPT rally to 30s. Needs to release the Keaken.
1 · Reply
Bernic88
Bernic88 Aug. 5 at 6:15 PM
$EYPT It’s really strange right now—all these high price targets, yet at the same time warnings about dilution and large short positions. I’m really curious to see what happens.
0 · Reply
TerryRowe307
TerryRowe307 Aug. 5 at 6:14 PM
$LVWR $EYPT $TOSHI $AMKR $EBAY LiveWire develops electric motorcycles, EyePoint advances retinal therapies, Toshi remains a speculative crypto asset, Amkor supports semiconductor packaging, and eBay generates resilient marketplace cash flow.
0 · Reply
Bernic88
Bernic88 Aug. 5 at 6:07 PM
0 · Reply
TickrTalk0007
TickrTalk0007 Aug. 5 at 3:44 PM
$EYPT bull trap with data on the horizon... binary to negative event in next few weeks...company is in quiet period.
4 · Reply
Olivia_Strickland
Olivia_Strickland Aug. 5 at 2:16 PM
$EYPT pushing 7.5% to 12.54, reclaiming the prior close. these breakout moves can fade fast. what level you guys watching here live tape on the breakout: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=eypt-bk-up-tape&utm_term=scanner&s=EYPT
1 · Reply
mattblankley
mattblankley Aug. 5 at 2:08 PM
$EYPT Added 100 more shares, totalling 13100 shares. This is me done until the read out. Good luck everyone.
0 · Reply
AnalyticalOne
AnalyticalOne Aug. 5 at 2:00 PM
$EYPT It's a great company, great products on the horizon and very solid progress but I'm not even sure that the readout will cause a price above $24 to $25 max, lol. Don't get me wrong, it's totally fine to keep cheering😉
1 · Reply
Latest News on EYPT
EyePoint reports Q2 EPS ($1.09), consensus (96c)

2026-08-05T11:40:45.000Z - 8 hours ago

EyePoint reports Q2 EPS ($1.09), consensus (96c)


EyePoint Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 8 hours ago

EyePoint Earnings release: Q2 2026


EyePoint Slides: Investor presentation

Aug 4, 2026, 9:00 AM EDT - 1 day ago

EyePoint Slides: Investor presentation


EyePoint price target lowered to $30 from $33 at JPMorgan

2026-07-22T10:55:27.000Z - 14 days ago

EyePoint price target lowered to $30 from $33 at JPMorgan


EyePoint to pay $4.6M to resolve False Claim Act allegations

2026-07-17T14:30:13.000Z - 19 days ago

EyePoint to pay $4.6M to resolve False Claim Act allegations


EyePoint initiated with a Buy at Stifel

2026-07-15T20:15:13.000Z - 20 days ago

EyePoint initiated with a Buy at Stifel


EyePoint Appoints Tarek S. Hassan, M.D.

Jul 13, 2026, 7:00 AM EDT - 23 days ago

EyePoint Appoints Tarek S. Hassan, M.D.


EyePoint assumed with an Overweight at Cantor Fitzgerald

2026-07-08T11:50:27.000Z - 4 weeks ago

EyePoint assumed with an Overweight at Cantor Fitzgerald


EyePoint price target raised to $65 from $29 at Chardan

2026-07-01T10:16:22.000Z - 5 weeks ago

EyePoint price target raised to $65 from $29 at Chardan


EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 9:00 AM EDT - 2 months ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum


EyePoint reports Q1 EPS (99c), consensus (81c)

2026-05-07T07:35:29.000Z - 3 months ago

EyePoint reports Q1 EPS (99c), consensus (81c)


EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Earnings Call Transcript: Q1 2026


EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Earnings release: Q1 2026


EyePoint Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

EyePoint Quarterly report: Q1 2026


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

EyePoint Proxy statement: Proxy filing


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

EyePoint Proxy statement: Proxy filing


EyePoint Slides: Investor presentation

Apr 23, 2026, 7:00 AM EDT - 3 months ago

EyePoint Slides: Investor presentation


EyePoint price target raised to $35 from $31 at Citi

2026-03-09T10:55:47.000Z - 5 months ago

EyePoint price target raised to $35 from $31 at Citi


EyePoint price target raised to $30 from $23 at H.C. Wainwright

2026-03-05T11:11:09.000Z - 5 months ago

EyePoint price target raised to $30 from $23 at H.C. Wainwright


EyePoint price target raised to $29 from $27 at Chardan

2026-03-04T19:55:31.000Z - 5 months ago

EyePoint price target raised to $29 from $27 at Chardan


EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Earnings Call Transcript: Q4 2025


EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Annual report: Q4 2025


EyePoint Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

EyePoint Earnings release: Q4 2025


EyePoint reports Q4 EPS (81c), consensus (75c)

2026-03-04T12:10:17.000Z - 5 months ago

EyePoint reports Q4 EPS (81c), consensus (75c)


EyePoint expects cash to fund operations into Q4 2027

2026-03-04T12:09:56.000Z - 5 months ago

EyePoint expects cash to fund operations into Q4 2027


EyePoint Slides: Investor presentation

Mar 2, 2026, 7:00 AM EST - 5 months ago

EyePoint Slides: Investor presentation


EyePoint price target raised to $36 from $33 at Mizuho

2026-02-19T12:28:49.000Z - 5 months ago

EyePoint price target raised to $36 from $33 at Mizuho


EyePoint appoints Campbell as Chief Commercial Officer

2026-02-18T12:05:24.000Z - 6 months ago

EyePoint appoints Campbell as Chief Commercial Officer


EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 6 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer


EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 7 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 7 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

EyePoint Slides: Investor presentation


EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 9 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference


EyePoint Slides: FY 2025

Nov 12, 2025, 10:40 AM EST - 9 months ago

EyePoint Slides: FY 2025


EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Earnings Call Transcript: Q3 2025


EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Quarterly report: Q3 2025


EyePoint Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

EyePoint Earnings release: Q3 2025


EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 10 months ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 10 months ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q2 2025


EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q2 2025


EyePoint Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q2 2025


EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum


EyePoint Slides: Investor Presentation

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation


EyePoint Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025


EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025


EyePoint Earnings release: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024


EyePoint Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Annual report: Q4 2024


EyePoint Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings release: Q4 2024


EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference


EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference


EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update


EyePoint Press release: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Press release: Status Update


EyePoint Slides: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Slides: Status Update


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


EyePoint Slides: FY 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Slides: FY 2025


EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024


EyePoint Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Quarterly report: Q3 2024


EyePoint Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Earnings release: Q3 2024


EyePoint Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 2:30 PM EDT - 2 years ago

EyePoint Transcript: UBS Virtual Ophthalmology Day


EyePoint Registration statement: Registration Filing

Aug 8, 2024, 8:00 AM EDT - 2 years ago

EyePoint Registration statement: Registration Filing


EyePoint Quarterly report: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Quarterly report: Q2 2024


EyePoint Earnings release: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Earnings release: Q2 2024


EyePoint Slides: Investor Presentation

Jul 9, 2024, 6:00 AM EDT - 2 years ago

EyePoint Slides: Investor Presentation


EyePoint Transcript: R&D Day 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: R&D Day 2024


EyePoint Press release: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: FY 2024


EyePoint Slides: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: FY 2024


EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024


EyePoint Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Quarterly report: Q1 2024


EyePoint Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Earnings release: Q1 2024


Poet5
Poet5 Aug. 5 at 7:41 PM
$EYPT The first two trials were outstanding in every metric, safety, efficacy, 40-50% reduced treatment burden compared to Eylea, neuroanatomical structural integrity. I cannot imagine how the naive population in phase III would not bode equal or superior to former heavily treated population. The fears expressed about dilution is absurd! The extremely strong expectations and increased range estimates 40-65.00 are based on non-superiority. The shorting to hedge thinking is of not absurd, a bit of a head fake!
0 · Reply
explover
explover Aug. 5 at 7:16 PM
$EYPT why would they report the quarterly without warning in such a haste and without a 10-Q? It makes some sense as positioning for an offering after a successful LUGANO readout.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 5 at 6:23 PM
$EYPT rally to 30s. Needs to release the Keaken.
1 · Reply
Bernic88
Bernic88 Aug. 5 at 6:15 PM
$EYPT It’s really strange right now—all these high price targets, yet at the same time warnings about dilution and large short positions. I’m really curious to see what happens.
0 · Reply
TerryRowe307
TerryRowe307 Aug. 5 at 6:14 PM
$LVWR $EYPT $TOSHI $AMKR $EBAY LiveWire develops electric motorcycles, EyePoint advances retinal therapies, Toshi remains a speculative crypto asset, Amkor supports semiconductor packaging, and eBay generates resilient marketplace cash flow.
0 · Reply
Bernic88
Bernic88 Aug. 5 at 6:07 PM
0 · Reply
TickrTalk0007
TickrTalk0007 Aug. 5 at 3:44 PM
$EYPT bull trap with data on the horizon... binary to negative event in next few weeks...company is in quiet period.
4 · Reply
Olivia_Strickland
Olivia_Strickland Aug. 5 at 2:16 PM
$EYPT pushing 7.5% to 12.54, reclaiming the prior close. these breakout moves can fade fast. what level you guys watching here live tape on the breakout: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=eypt-bk-up-tape&utm_term=scanner&s=EYPT
1 · Reply
mattblankley
mattblankley Aug. 5 at 2:08 PM
$EYPT Added 100 more shares, totalling 13100 shares. This is me done until the read out. Good luck everyone.
0 · Reply
AnalyticalOne
AnalyticalOne Aug. 5 at 2:00 PM
$EYPT It's a great company, great products on the horizon and very solid progress but I'm not even sure that the readout will cause a price above $24 to $25 max, lol. Don't get me wrong, it's totally fine to keep cheering😉
1 · Reply
buylocellhi
buylocellhi Aug. 5 at 1:53 PM
$EYPT the volume and the price increase should tell you everything!
0 · Reply
buylocellhi
buylocellhi Aug. 5 at 1:48 PM
$EYPT when it hits $15 the shorts are gonna start panicking
0 · Reply
buylocellhi
buylocellhi Aug. 5 at 1:47 PM
$EYPT squeeze to 30 bucks!
0 · Reply
buylocellhi
buylocellhi Aug. 5 at 1:45 PM
$EYPT cover!!!!
0 · Reply
Bernic88
Bernic88 Aug. 5 at 1:37 PM
$EYPT 👀
0 · Reply
Fosco_
Fosco_ Aug. 5 at 1:36 PM
$EYPT Guys, don’t buy the BS narrative "big players positioning for serious drawdown" Remember DAVIO 2, December 4th 2023. EYPT had drifted from $8 all the way down to $4.78 in the weeks before topline. Options flow was ugly, sentiment was awful. Data dropped, stock went +187% on the day, from $4.78 to $13+. Everyone who read the pre-data tape as a signal got destroyed. LUGANO is the same playbook: non-inferiority design (DURAVYU just has to match Eylea, already done in Phase 2), three clean DSMCs with 5% discontinuation vs 10% sector average, and 14 analysts all Buy with zero Hold. Day to Day trading is daily noise, P3 data is the one time binary.
1 · Reply
rizzato
rizzato Aug. 5 at 12:47 PM
$EYPT I’m asking myself if the institution or big shareholders that are adding more shares during the drop are more informed than us regarding the coming data read out. My opinion is for sure yes is impossible that they are investing million dollar without any news that the market doesn’t know.
1 · Reply
rizzato
rizzato Aug. 5 at 12:41 PM
$EYPT They trust the company and are adding more shares waiting for the data https://www.tipranks.com/news/the-fly/citi-opens-upside-90-day-catalyst-watch-on-eyepoint-into-data-thefly-news?mod=mw_quote_news
0 · Reply
mattblankley
mattblankley Aug. 5 at 12:16 PM
$EYPT The earnings has been released today and it mainly highlights 2 key points. Firstly, the data will be released this month. Secondly, their cash runway will be enough up until 2027 Q4. This makes the binary event even more volatile. If the data is not good, slightly disappoints and sells off, the Company is at risk of facing insolvency, as they will not be able to raise any capital. Secondly, upon good data, there will for sure be a capital raise, which will extend their cash runway. They may do what DFTX did recently. Raise capital upon release of good data, and raise additional capital upon the release of another good data in October. Either way, we are all on the same boat. If the data disappoints, all the retail shareholders go down with the Company (your stop loss will be unlikely to hit if one of the big institutions sell straight away, as the stock will go from $11 to $5-6 within split seconds. If the data does not disappoint, we all rise with the Company. Good luck!
1 · Reply
EndGD
EndGD Aug. 5 at 11:36 AM
$EYPT In light of the upcoming topline data readout for the pivotal Phase 3 LUGANO clinical trial in wet AMD, EyePoint will not be hosting an earnings-related conference call. The Company plans to provide an update in conjunction with topline data.
0 · Reply
KimboIce
KimboIce Aug. 5 at 11:18 AM
$EYPT ER out . Nothing to see here . Disregard my paranoid posts .
1 · Reply
Gshc22
Gshc22 Aug. 5 at 11:17 AM
$EYPT Q2 out !
0 · Reply